在肝脑病患者中对利法西明的获取障碍的评估,使用裁决的索赔数据
Arun Jesudian1, Patrick Gagnon-Sanschagrin2, Jessica Maitland3
1Weill Cornell Medicine, 1283 York Avenue, New York, NY, 10065, USA.
对利法西明的获取障碍,通常是由于申请被拒绝,增加了肝脑病患者的住院和医疗费用. 解决这些差距对于更好的高等教育管理和减少医疗保健支出至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药物经济学 药物经济学
- 获得医疗保健 获得医疗保健 获得医疗保健
背景情况:
- 持续的利法西明治疗与肝脏脑病变 (HE) 患者的住院减少有关.
- 对利法西明的潜在接入障碍可能会阻碍治疗的坚持和结果.
- 这项研究调查了rifaximin获取差距及其对美国HE患者的影响.
研究的目的:
- 评估HE患者获得rifaximin的缺口.
- 评估治疗缺口对住院住院的影响,特别是由于申请被拒绝而造成的缺口.
- 分析rifaximin获取障碍对HE患者医疗保健成本的影响.
主要方法:
- 利用了IQVIA PharMetrics® Plus数据库,与纵向访问和裁决数据 (2015-2022) 相连接.
- 已识别的成年HE患者至少有一次付费的利法西明处方填充.
- 评估了指数日期后12个月内的治疗差距,并比较了患有和没有排斥相关差距的患者之间的住院和成本.
主要成果:
- 超过94%的患者在一年内经历了治疗缺口.
- 启动缺口,主要是由于申请被拒绝 (77.7%),影响了34.8%的患者.
- 与没有差距的患者相比,有差距的患者 (队列2) 的OHE住院率是1.55倍高,每月每患者的费用比没有差距的患者 (队列1) 多1579美元.
结论:
- 处方要求的拒绝经常导致利法西明启动和治疗缺口的延迟.
- 对利法西明的获取障碍与医院住院和医疗保健费用增加有关.
- 改善利法西明的获取对于优化医疗保健患者护理和减少经济负担至关重要.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:42Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Absorption: Factors Affecting GI Absorption
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
